GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (OTCPK:SHIEF) » Definitions » Asset Impairment Charge

SHIEF (Shield Therapeutics) Asset Impairment Charge : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shield Therapeutics Asset Impairment Charge?

Shield Therapeutics's Asset Impairment Charge for the six months ended in Jun. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.


Shield Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Shield Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Asset Impairment Charge Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shield Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.


Shield Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Shield Therapeutics Business Description

Traded in Other Exchanges
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.

Shield Therapeutics Headlines